|
KMID : 0032220200320030230
|
|
Annals of Dermatology
2020 Volume.32 No. 3 p.230 ~ p.232
|
|
|
Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
|
|
Ko Jung-Woo
Park Kyung-Duck
Lee Young
Lee Jeung-Hoon
Hong Dong-Kyun
|
|
|
Abstract
|
|
|
|
Exenatide extended-release was recently developed as an antidiabetic drug; it acts as a glucagon-like peptide-1 receptor agonist. A 54-year-old male visited our clinic complaining of a subcutaneous tender nodule on his left thigh that had developed over the course of 1 week. The patient had received exenatide extended-release injections for 5 months to treat diabetes. A histopathologic examination showed septal and lobular panniculitis with lymphohistiocyte and eosinophil infiltration. The patient was diagnosed with eosinophilic panniculitis (EP) due to exenatide extended-release injection. EP is a rare type of panniculitis characterized by a prominent infiltrate of eosinophils in the subcutaneous fat layer. It is a histologic reaction pattern that is associated with various clinical conditions. Among the injection-site reactions reported in exenatide extended-release users, injection-site nodules occur infrequently. Clinicians who treat diabetics who use exenatide extended-release should be aware of the possible occurrence of injection-site nodules.
|
|
|
KEYWORD
|
|
|
Diabetes mellitus, Exenatide, Panniculitis
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|